Vas­ant Narasimhan to suc­ceed Jimenez at No­var­tis

BioSpectrum (India) - - PEOPLE NEWS -

No­var­tis Chief Ex­ec­u­tive Joseph Jimenez will re­tire in 2018, with chief drug de­vel­oper Vas­ant Narasimhan tak­ing over as CEO start­ing in Fe­bru­ary. Jimenez, 58, is step­ping down fol­low­ing a decade at No­var­tis af­ter hav­ing suc­cess­fully se­cured U S ap­proval for a new gene ther­apy for leukemia but be­fore No­var­tis re­turned to sales growth, which the com­pany has fore­cast will re­sume in 2018.

A No­var­tis em­ployee since 2005, Narasimhan has in­creased his pub­lic pres­ence at No­var­tis since be­com­ing global head of drug de­vel­op­ment and chief med­i­cal of­fi­cer in 2016. Just 41, he is among a new gen­er­a­tion of youth­ful leaders at No­var­tis that in­clude head re­searcher Jay Brad­ner at the No­var­tis In­sti­tutes For Bio­med­i­cal Re­search who have sought to im­prove the process in which drugs move from re­search to ac­tu­ally be­com­ing a com­mer­cial prod­uct.

Jimenez ar­rived in 2007 to lead No­var­tis's con­sumer health di­vi­sion and rose to CEO in 2010 un­der for­mer Chair­man Daniel Vasella, who left in 2013. Jimenez is hand­ing over the reins at a cru­cial junc­ture, with the drug­maker yet to make a de­ci­sion on the fu­ture of its ail­ing Al­con eye-care busi­ness or its stake in crosstown ri­val Roche Hold­ing AG.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.